- Research article
- Open Access
Can presepsin uniformly respond to various pathogens? - an in vitro assay of new sepsis marker -
BMC Immunology volume 21, Article number: 33 (2020)
Presepsin (soluble CD14 subtype) is a novel biomarker of sepsis used for early diagnosis. Originally, CD14 is known as the pattern recognition receptor for the lipopolysaccharide (LPS)/LBP complexes, and the diagnostic value of this molecule for gram-positive bacteria, which contain less amount of LPS, is uncertain. To confirm its effectiveness in the diagnosis of bacteremia caused by gram positive bacteria, and to evaluate the interspecies difference of presepsin production against various bacterial strains, we conducted an in vitro assay to evaluate presepsin levels in response to five Gram negative and four Gram positive bacteria.
Whole blood was yielded from five healthy volunteers and co-cultured with bacterial strains at 37 °C for 4 h. Twenty seven clinical isolates of nine species (E. coli, K. pneumoniae, E. cloacae, P. aeruginosa, S. maltophilia, S. aureus, S. pyogenes, B. cereus, and C. striatum) derived from blood cultures of non-neutropenic bacteremia patients were used. Culture supernatants were harvested and presepsin levels were measured. The presepsin level in the gram-negative bacteria 273 (218–352) pg/mL was significantly higher than in the gram-positive bacteria 200 (143–275) pg/mL (p = 0.0002). The presepsin levels were significantly lower in C. striatum, in comparison to other bacteria, and S. pyogenes showed similar results. And the presepsin levels in P. aeruginosa were significantly lower compared to E. cloacae, K. pneumoniae, and S. aureus.
Presepsin production can also be evoked by gram-positive bacteria, and interspecies differences of presepsin response may exist, which should be considered in the diagnosis of sepsis, especially in certain gram-positive bacteremia such as S. pyogenes or C. striatum.
Presepsin (soluble CD14 subtype) is a novel biomarker of sepsis . The plasma presepsin level rises as early as within 2 h of inflammation onset, which is even earlier than C-reactive protein (CRP), procalcitonin, or interleukin-6 (IL-6) [2,3,4]. With a high specificity for bacterial infections, presepsin has proved useful in early diagnosis and is a prognostic marker of severe sepsis [3,4,5,6,7,8]. In recent years, the clinical importance of this molecule has been intensively discussed in various categories of infection such as surgery , burn , neonatal sepsis , and febrile neutropenia [12, 13]. Moreover, recent meta-analyses showed its efficacy in the diagnosis of sepsis [14, 15].
CD14 is the receptor for lipopolysaccharide (LPS) / LPS – binding protein (LPS/LBP) complexes  and is released in the early phase of infection. As LPS represents a characteristic attribute of gram-negative bacteria, the diagnostic value of this molecule for gram-positive bacteria, which contain less LPS, is uncertain.
In this study, we conducted a simple in vitro assay to evaluate presepsin levels in response to various gram-negative and gram-positive bacterial strains. Although other factors might influence the presepsin altitude in real septic patient’s environment, we tried to clarify the interspecies differences in response to various pathogens with this in vitro assay.
Figure 1 shows the comparison of presepsin levels between the gram-positive and gram-negative bacteria. The presepsin level in the gram-negative bacteria 273 (median, IQR = 218–352) pg/mL was significantly higher than in the gram-positive bacteria 200 (143–275) pg/mL (p = 0.0002, Wilcoxon rank sum test). The presepsin values in control group was 84.3 (73.9–103) pg/mL.
Figure 2 shows the comparison of the presepsin released in the assay of each species. The strains were sorted in the descending order of median values of the amount of presepsin released. The median (IQR) of the presepsin levels in gram-negative bacteria were Enterobacter cloacae 330 (246–462) pg/mL, Klebsiella. pneumoniae 301 (229–378) pg/mL, Stenotrophomonas maltophilia 284.5 (202.25–396) pg/mL, Escherichia coli 251.5 (175–289.25) pg/mL, and Pseudomonas aeruginosa 197 (169–274) pg/mL.
The presepsin levels in the gram-positive bacteria were Staphylococcus aureus 282 (225–452) pg/mL, Bacillus cereus 197 (140–324) pg/mL, Streptococcus pyogenes 171 (150–213) pg/mL, and Corynebacterium striatum 136 (119–193) pg/mL.
The Steel-Dwass test revealed that the presepsin levels were significantly lower in C. striatum, in comparison to E. cloacae (p = 0.0003), K. pneumoniae (p = 0.0005), S. aureus (p = 0.0005), S. maltophilia (p = 0.018), and E. coli (p = 0.047), respectively.
The presepsin levels were also significantly lower in S. pyogenes in comparison to E. cloacae (p = 0.0003), K. pneumoniae (p = 0.0006), and S. aureus (p = 0.0007), respectively.
The presepsin levels in P. aeruginosa were significantly lower compared to E. cloacae (p = 0.013).
Presepsin is a subtype of the N-terminal fragment of soluble CD14 with a molecular weight of 13 kDa. CD14 is known as the pattern recognition receptor (PRR) for the LPS-LBP complexes expressed on the cell membrane of the phagocytes. During phagocytosis, the CD14 molecule is internalized with the bacteria and cleaved into presepsin after phagolysosomal processing, and released into the plasma [1, 4, 5, 17].
Previous studies had focused on the clinical aspects of this molecule, such as sensitivity, specificity or positive predictive value in the diagnosis of infectious diseases. For example, higher presepsin level is indicative of severe sepsis and is also associated with poor prognosis [3,4,5,6,7,8, 14, 15]. In those studies, the species of the bacteria causing sepsis were not considered in detail.
Because presepsin derives from CD14, one of the major PRRs, the degree of its response is presumed to reflect the surface structure of the confronting pathogen. Since LPS is specific for gram-negative bacteria, we attempted to evaluate the response of this molecule towards gram-positive bacteria. This is important because the existence of an interspecies difference might affect the reliability of presepsin as an early marker of infectious diseases.
Thus, we designed an in vitro assay to evaluate the presepsin levels in response to various strains including five gram-negative and four gram-positive bacteria. The assay system mimics the situation in bacteremia, reflecting the immediate phagocyte-bacterial interaction with the help of other circulating blood cells, plasma proteins or the complement system. Generally, the host-microbe interaction is difficult to evaluate because there are cascades of complex intervening inflammatory responses. However, unlike other assays, our system involves minimal requirements of host-microbe immunity. Therefore, evaluations in a direct and in a real time manner can be achieved.
Our results suggested that presepsin production can be also evoked by gram-positive bacteria. However, presepsin levels in response to the gram-positive bacteria were lower than those of gram-negative bacteria, as expected because LPS is a characteristic attribute of gram-negative bacteria. This trend was prominent in C. striatum and S. pyogenes. But some gram-positive organisms like S. aureus evoked relatively high levels of presepsin and gram-negative bacteria like P. aeruginosa evoked lower levels. This could probably be due to the difference in the immunogenicity or phagocytosis evocativenesss (sensitivity) among the species. The association of CD14 ligands, other than LPS, might influence its production. Or, the low presepsin level in response to S. pyogenes might be partly explained by phagocytosis escaping mechanisms . Further analyses of the membrane structures or other factors affecting the levels of presepsin release should be carried out to elucidate the reasons for such a response.
This study has a few limitations. First, the host immune profile was not analyzed in detail, except that the number of neutrophils and the baseline presepsin levels were confirmed to be equivalent. We cannot exclude the influence of other immunological factors, such as lymphocyte subsets, complement, or cytokines. Second, we only used clinical isolates. We selected typical non-neutropenic bacteremia cases as a source of the bacterial strains. The cases showed bacteremia in the absence of neutropenia, immunosuppressants, and mechanical obstructions, which indicated that they are virulent enough to cause bacteremia in the general population. We intended to reproduce bacteremia in vitro with real world strains; however, whether they can be considered representative strains is debatable. All the species were correctly identified by biochemical analysis and confirmed by MALDI-TOF-MS. Moreover, to avoid potential strain bias, we integrated the data of 3 strains for one species. Third, the presepsin levels observed in this study cannot be applied in clinical settings. The values discussed here are a relative comparison among the species and do not reflect the cut-off values of either sepsis or the septic shock diagnostic criteria.
Taking the strengths and limitations of this study into consideration, our result is still meaningful because our assay mimics the clinical situation of bacteremia in which bacteria encounters immune cells in the blood, and we can directly evaluate the total immune response. Our experiment also warrants the need to consider the interspecies difference when presepsin is used as a diagnostic tool in sepsis.
In conclusion, using a simple in vitro presepsin releasing assay, we found that presepsin production can also be evoked by gram-positive bacteria, though the levels were significantly lower in comparison to the gram-negative bacteria. We also found interspecies differences in the presepsin response levels, which might be important in the diagnosis of infectious diseases caused by certain gram-positive bacteria, such as S. pyogenes or C. striatum. To our knowledge, this is the first report using an in vitro presepsin assay, and focusing on the difference of its responsiveness as a PRR against various bacterial species. Our experiment warrants the need to consider the interspecies difference when presepsin is used as a diagnostic tool in sepsis caused by certain gram-positive bacteria, such as S. pyogenes or C. striatum.
The system is a co-culture assay using whole blood and the bacterial strains obtained from blood culture.
Whole blood preparation
Venous blood samples were drawn from five healthy volunteers. All the participants had normal renal and hepatic function, normal leukocyte count, and no previous medical history. After phlebotomy, whole blood was immediately heparinized and prepared for the co-culture assay.
We selected five gram-negative bacteria (Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia), and four gram-positive bacteria (Staphylococcus aureus, Streptococcus pyogenes, Bacillus cereus, and Corynebacterium striatum); three strains per species were examined. Twenty seven clinical isolates were obtained from the blood cultures of 27 different bacteremic patients, all of them demonstrating septic shock and/or disseminated intravascular coagulation at the time of blood culture. They neither had neutropenia, immunosuppression, nor mechanical obstructions in urinary, biliary, or gastrointestinal tracts.
The strains were identified by conventional biochemical methods and were confirmed by matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF/MS) (Biotyper ver.3.1, Burker Daltonics, Bremen, Germany).
Co-culture & measurement of presepsin level
As written above, fifteen co-cultures per each species (five volunteers for three strains) were examined. The bacterial strains were recovered from the deep freezer and sub-cultured in blood agar plates before use. Bacterial counts were determined by colorimetric analysis, and the concentrations were adjusted to obtain 2 × 106 CFUs in 40 μL of saline.
The bacterial suspension and 400 μL of the whole blood were mixed in the microplates. The mixture was incubated at 37 °C for 4 h with shaking and culture supernatant was harvested. Presepsin measurement was made by a rapid chemiluminescent enzyme immunoassay on the fully automated PATHFAST® immunoanalyzer (Mitsubishi Chemical Medience Corporation, Tokyo, Japan) .
The data are represented as median (interquartile range; IQR). In all analyses, p < 0.05 was considered statistically significant. Wilcoxon rank sum test was performed for comparisons of two independent groups of sampled data.
The Kruskal–Wallis test and Steel-Dwass test was performed to compare independent samples of equal or different sample sizes. We analyzed the data using the statistical software JMP® 10 (SAS Institute Inc., Cary, NC, USA).
Availability of data and materials
The datasets used and/or analyzed during the current study available from the corresponding author on reasonable request.
LPS binding protein
Matrix-assisted laser desorption ionization-time of flight mass spectrometry
Colony forming unit
Pattern recognition receptor,
Yaegashi Y, Shirakawa K, Sato N, et al. Evaluation of a newly identified soluble CD14 subtype as a marker for sepsis. J Infect Chemother. 2005;11:234–8.
Naitou K, Shirakawa K, Hirose JJ, et al. The new sepsis marker, sCD14-ST, induction mechanism in the rabbit sepsis models. Crit Care. 2010;14(Suppl 2):P19.
Shozushima T, Takahashi G, Matsumoto N, Kojika M, Okamura Y, Endo S. Usefulness of presepsin (sCD14-ST) measurements as a marker for the diagnosis and severity of sepsis that satisfied diagnostic criteria of systemic inflammatory response syndrome. J Infect Chemother. 2011;17:764–9.
Nakamura M, Takeuchi T, Naito K, et al. Early elevation of plasma soluble CD14 subtype, a novel biomarker for sepsis, in a rabbit cecal ligation and puncture model. Crit Care. 2008;12(Suppl 2):P194.
Endo S, Suzuki Y, Takahashi G, et al. Usefulness of presepsin in the diagnosis of sepsis in a multicenter prospective study. J Infect Chemother. 2012;18:891–7.
Ulla M, Pizzolato E, Lucchiari M, et al. Diagnostic and prognostic value of presepsin in the management of sepsis in the emergency department: a multicenter prospective study. Crit Care. 2013;17:R168.
Liu B, Chen YX, Yin Q, Zhao YZ, Li CS. Diagnostic value and prognostic evaluation of Presepsin for sepsis in an emergency department. Crit Care. 2013;17:R244.
Masson S, Caironi P, Fanizza C, et al. Circulating presepsin (soluble CD14 subtype) as a marker of host response in patients with severe sepsis or septic shock: data from the multicenter, randomized ALBIOS trial. Intensive Care Med. 2015;41:12–20.
Novelli G, Morabito V, Ferretti G, et al. Pathfast presepsin assay for early diagnosis of bacterial infections in surgical patients: preliminary study. Transplant Proc. 2013;45:2750–3.
Cakır Madenci Ö, Yakupoğlu S, Benzonana N, et al. Evaluation of soluble CD14 subtype (presepsin) in burn sepsis. Burns. 2014;40:664–9.
Pugni L, Pietrasanta C, Milani S, et al. Presepsin (soluble CD14 subtype): reference ranges of a new sepsis marker in term and preterm neonates. PLoS One. 2015;10:e0146020.
Koizumi Y, Shimizu K, Shigeta M, et al. Plasma presepsin level is an early diagnostic marker of severe febrile neutropenia in hematologic malignancy patients. BMC Infect Dis. 2017;17:27.
Baraka A, Zakaria M. Presepsin as a diagnostic marker of bacterial infections in febrile neutropenic pediatric patients with hematological malignancies. Int J Hematol. 2018;108:184–91.
Zhang X, Liu D, Liu YN, Wang R, Xie LX. The accuracy of presepsin (sCD14-ST) for the diagnosis of sepsis in adults: a meta-analysis. Crit Care. 2015;19:323.
Bellos I, Fitrou G, Pergialiotis V, Thomakos N, Perrea DN, Daskalakis G. The diagnostic accuracy of presepsin in neonatal sepsis: a meta-analysis. Eur J Pediatr. 2018;177:625–32.
Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science. 1990;249:1431–3.
Arai Y, Mizugishi K, Nonomura K, Naitoh K, Takaori-Kondo A, Yamashita K. Phagocytosis by human monocytes is required for the secretion of presepsin. J Infect Chemother. 2015;21:564–9.
Walker MJ, Barnett TC, McArthur JD, et al. Disease manifestations and pathogenic mechanisms of group a streptococcus. Clin Microbiol Rev. 2014;27:264–301.
Okamura Y, Yokoi H. Development of a point-of-care assay system for measurement of presepsin (sCD14-ST). Clin Chim Acta. 2011;412:2157–61.
None of the authors have financial relationships with any commercial entity with an interest in the subject of this manuscript.
Ethics approval and consent to participate
Written consent was obtained from the participants after verbal and written information provision. Permission for this study was provided by the Institutional Ethics Committee at Aichi Medical University. All the procedures have been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.
Consent for publication
None of the authors have financial and non-financial competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Koizumi, Y., Sakanashi, D., Mohri, T. et al. Can presepsin uniformly respond to various pathogens? - an in vitro assay of new sepsis marker -. BMC Immunol 21, 33 (2020). https://doi.org/10.1186/s12865-020-00362-z
- Gram-positive bacteria
- Gram-negative bacteria
- In vitro assay